読み込み中
TriSalus Life Sciences, Inc. is an immunotherapy firm dedicated to the research, development, and market introduction of treatments that leverage the body's immune system, primarily targeting liver and pancreatic cancers. The company's product portfolio includes the TriNav Infusion System, designed for hepatic arterial infusion to treat liver tumors, and the Pancreatic Retrograde Venous Infusion System, which addresses pancreatic tumors. Additionally, TriSalus is advancing SD-101, an investigational immunotherapeutic that incorporates pressure-enabled drug delivery technology. This experimental therapy is currently being explored for its application in hepatocellular carcinoma, intrahepatic cholangiocarcinoma, uveal melanoma with liver metastases, pancreatic ductal adenocarcinoma with liver metastases, colorectal cancer with liver metastases, and primary pancreatic cancers. The company's operations are headquartered in Westminster, Colorado.
前日終値
$4.06
−$0.07 · -1.69%
日中の時刻はETです。市場データは遅延する場合があります。
TriSalus Life Sciences, Inc. is an immunotherapy firm dedicated to the research, development, and market introduction of treatments that leverage the body's immune system, primarily targeting liver and pancreatic cancers. The company's product portfolio includes the TriNav Infusion System, designed for hepatic arterial infusion to treat liver tumors, and the Pancreatic Retrograde Venous Infusion System, which addresses pancreatic tumors. Additionally, TriSalus is advancing SD-101, an investigational immunotherapeutic that incorporates pressure-enabled drug delivery technology. This experimental therapy is currently being explored for its application in hepatocellular carcinoma, intrahepatic cholangiocarcinoma, uveal melanoma with liver metastases, pancreatic ductal adenocarcinoma with liver metastases, colorectal cancer with liver metastases, and primary pancreatic cancers. The company's operations are headquartered in Westminster, Colorado.
日中レンジ
現在 $4.06
52週レンジ
現在 $4.06
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
77
割安
センチメント
54
まちまち
リスク
62
高リスク
モメンタム
35
弱含み
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
TriSalus Life Sciences, Inc. is an immunotherapy firm dedicated to the research, development, and market introduction of treatments that leverage the body's immune system, primarily targeting liver and pancreatic cancers. The company's product portfolio includes the TriNav Infusion System, designed for hepatic arterial infusion to treat liver tumors, and the Pancreatic Retrograde Venous Infusion System, which addresses pancreatic tumors. Additionally, TriSalus is advancing SD-101, an investigational immunotherapeutic that incorporates pressure-enabled drug delivery technology. This experimental therapy is currently being explored for its application in hepatocellular carcinoma, intrahepatic cholangiocarcinoma, uveal melanoma with liver metastases, pancreatic ductal adenocarcinoma with liver metastases, colorectal cancer with liver metastases, and primary pancreatic cancers. The company's operations are headquartered in Westminster, Colorado.
日中レンジ
現在 $4.06
52週レンジ
現在 $4.06
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 4515.1万 USD | 2943.1万 USD | 1851.1万 USD | 1239.8万 USD | 840.1万 USD |
| 売上原価 | 696.5万 USD | 410.3万 USD | 260.5万 USD | 225.8万 USD | 119.3万 USD |
| 粗利益 | 3818.6万 USD | 2532.8万 USD | 1590.6万 USD | 1014万 USD | 720.8万 USD |
| 研究開発 | 1496.5万 USD | 1768.8万 USD | 2983.5万 USD | 2135.8万 USD | 1422.4万 USD |
| 販売・一般管理 | 5016.7万 USD | 4380.5万 USD | 4054.6万 USD | 2522.1万 USD | 1701.6万 USD |
| 営業費用 | 6513.2万 USD | 6149.3万 USD | 7038.1万 USD | 4657.9万 USD | 3124万 USD |
| 受取利息 | 55.5万 USD | 40.4万 USD | 43.1万 USD | 18万 USD | — |
| 支払利息 | 554.4万 USD | 309万 USD | 1.6万 USD | 1000 USD | 176.1万 USD |
| 減価償却費と償却費 | 62.6万 USD | 74.4万 USD | 68.4万 USD | 39.8万 USD | 46.4万 USD |
| 営業利益 | −2694.6万 USD | −3616.5万 USD | −5447.5万 USD | −3643.9万 USD | −2403.2万 USD |
| 純利益 | −3922.7万 USD | −3323.3万 USD | −5936.3万 USD | −4718.7万 USD | −2884.5万 USD |
会社概要が更新されました 2026年10月11日.
発表済み実績と利用可能なコンセンサス予想。
発表済み実績と利用可能なコンセンサス予想。
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$11.00
上昇余地（170.94%）この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI565.23万0.00%2.3兆 USD0.03%$381.94+0.63%
iShares Russell 2000 ETFIWM471.4万0.01%787.4億 USD0.19%$278.94+0.49%
Vanguard Extended Market ETFVXF270.15万0.00%954億 USD0.05%$235+0.80%
iShares Russell 2000 Growth ETFIWO171.13万0.01%139.17億 USD0.24%$356.78+0.94%
Vanguard Russell 2000 ETFVTWO135.94万0.01%180億 USD0.06%$112.66+0.50%
Invesco Dorsey Wright SmallCap Momentum ETFDWAS121.94万0.31%3.99億 USD0.60%$107.24+1.40%
iShares Micro-Cap ETFIWC57.35万0.04%13.17億 USD0.60%$183+0.11%
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM26万0.22%1.17億 USD0.73%$15.9402+0.25%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOInvesco Dorsey Wright SmallCap Momentum ETFDWASiShares Micro-Cap ETFIWCEA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
